Knight Therapeutics Valuation
| GUD Stock | CAD 5.45 0.02 0.37% |
At this time, the firm appears to be overvalued. Knight Therapeutics secures a last-minute Real Value of C$4.68 per share. The latest price of the firm is C$5.45. Our model forecasts the value of Knight Therapeutics from analyzing the firm fundamentals such as Current Valuation of 428.49 M, return on equity of -0.0221, and Profit Margin of (0.05) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Knight Therapeutics' valuation include:
Price Book 0.7721 | Enterprise Value 428.5 M | Enterprise Value Ebitda 11.629 | Price Sales 1.7571 | Forward PE 263.1579 |
Overvalued
Today
Please note that Knight Therapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Knight Therapeutics is based on 3 months time horizon. Increasing Knight Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Knight Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Knight Stock. However, Knight Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.45 | Real 4.68 | Hype 5.44 | Naive 5.38 |
The intrinsic value of Knight Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Knight Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Knight Therapeutics helps investors to forecast how Knight stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Knight Therapeutics more accurately as focusing exclusively on Knight Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Knight Therapeutics' intrinsic value based on its ongoing forecasts of Knight Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Knight Therapeutics' closest peers.
Knight Therapeutics Investments |
|
Knight Valuation Trend
Knowing Knight Therapeutics' actual value is paramount for traders to make sound investment determinations. Knight Therapeutics' real value is not only important for the investor to make better decisions but also for a more accurate overall view of Knight Therapeutics' financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Knight Therapeutics' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.
Knight Market Cap
Knight Therapeutics is one of the top stocks in market capitalization category among its peers. Market capitalization of Health Care industry is currently estimated at about 23.45 Billion. Knight Therapeutics holds roughly 550.47 Million in market capitalization claiming about 2.35% of equities under Health Care industry.Knight Therapeutics Total Value Analysis
Knight Therapeutics is currently forecasted to have takeover price of 428.49 M with market capitalization of 550.47 M, debt of 17.85 M, and cash on hands of 302 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Knight Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
| 428.49 M | 550.47 M | 17.85 M | 302 K |
Knight Therapeutics Investor Information
About 45.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.77. Some equities with similar Price to Book (P/B) outperform the market in the long run. Knight Therapeutics has Price/Earnings (P/E) ratio of 133.9. The entity recorded a loss per share of 0.16. The firm had not issued any dividends in recent years. Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company was incorporated in 2013 and is headquartered in Montreal, Canada. KNIGHT THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in Canada and is traded on Toronto Stock Exchange. To learn more about Knight Therapeutics call Jonathan Goodman at 514-484-4483 or check out https://www.gud-knight.com.Knight Therapeutics Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The recent return on assets of Knight suggests not a very effective usage of assets in June.Knight Therapeutics Ownership Allocation
Knight Therapeutics maintains a total of 101.38 Million outstanding shares. Knight Therapeutics holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Knight Therapeutics Profitability Analysis
The company reported the revenue of 328.2 M. Net Loss for the year was (16.84 M) with profit before overhead, payroll, taxes, and interest of 138.06 M.About Knight Therapeutics Valuation
The stock valuation mechanism determines the current worth of Knight Therapeutics on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Knight Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Knight Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Knight Therapeutics's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Knight Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Knight Therapeutics. We calculate exposure to Knight Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Knight Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 152.7 M | 160.3 M | |
| Pretax Profit Margin | (0.07) | (0.06) | |
| Operating Profit Margin | 0.02 | 0.02 | |
| Net Loss | (0.05) | (0.05) | |
| Gross Profit Margin | 0.33 | 0.64 |
8 Steps to conduct Knight Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Knight Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Knight Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Knight Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Knight Therapeutics' revenue streams: Identify Knight Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Knight Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Knight Therapeutics' growth potential: Evaluate Knight Therapeutics' management, business model, and growth potential.
- Determine Knight Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Knight Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Other Information on Investing in Knight Stock
Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.